Endpoint events | |
---|---|
Primary outcomes | |
 Glycemic parameters | Normal range reference |
 Fasting blood glucose | < 100.9 mg/dL |
 Glycosylated hemoglobin/HbA1c | < 5.7% |
 Fructosamine | 200–285 μmol/L [63] |
 GlycoMark | ~ 180 mg/dL |
 Fasting insulin | < 25 μU/L |
 Absence of high HOMA-Insulin Resistance | General US adult population: < 2.73 vs. ≥ 2.73 [63] |
 Quantitative Insulin Sensitivity Check Index | ~ 100% [66] |
 Pancreatic β-cell function | ~ 100% [66] |
Secondary outcomes | |
 Lipid profile | |
  Total cholesterol | ≤ 19 years: < 170 mg/dL; ≥ 20 years: 125–200 mg/dL |
  Low-density lipoprotein | < 100 mg/dL |
  High-density lipoprotein | ≤ 19 years: > 45 mg/dL; ≥ 20 years men: ≥ 40 mg/dL; ≥ 20 years women: ≥ 50 mg/dL [129] |
  Triglycerides | < 150 mg/dL [130] |
 Inflammation | |
  High-sensitivity C-reactive protein (hs-CRP) | Variesa |
Progression to type-2 diabetes (T2D) (according to 2016 ADA diagnostic criteria [39, 40]) |